Developing a new treatment and companion diagnostic to improve outcomes for glioblastoma patientsbroad
GLIOBREAK · Horizon Europe grant · 2026-05-01–2028-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2025-TRANSITIONOPEN · scheme HORIZON-EIC · topic HORIZON-EIC-2025-TRANSITIONOPEN. CORDIS record →
Objective
Glioblastoma (GBM) remains a devastating brain cancer with limited treatment advances and poor survival outcomes. The GLIOBREAK project aims to develop BEA-17, a first-in-class oral small molecule that degrades epigenetic regulators LSD1 and CoREST, thereby reversing GBM immune evasion and enhancing responsiveness to immunotherapy.The main objectives are to advance BEA-17 and its biomarker-driven companion diagnostic from validated laboratory stage (TRL4) to early clinical readiness (TRL6). This will be achieved through scalable GMP manufacturing, GLP-compliant safety and pharmacokinetic studies, efficacy validation in preclinical models, biomarker discovery and validation, and regulatory preparation including orphan drug designation.GLIOBREAK directly addresses key challenges outlined in the EICT work programme by proposing a novel immuno-epigenetic therapy targeting GBM’s immunosuppressive microenvironment, combined with precision biomarker-based patient stratification to improve clinical outcomes. This aligns with Europe’s Beating Cancer Plan and EU priorities for innovative, personalized oncology medicines.By integrating fundamental biological insights with cutting-edge therapeutic and diagnostic development, GLIOBREAK aims to deliver a transformative new treatment option for GBM patients and establish a platform for expanding into other difficult-to-treat cancers, reinforcing Europe’s leadership in precision immuno-oncology.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| BEACTICA THERAPEUTICS AB | SE | coordinator | €1,643,722 | Yes |
| KATHOLIEKE UNIVERSITEIT LEUVEN | BE | participant | €930,393 |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.